844 / 1138
MIRALBELL IJROBP 2012
•
Low α/β for all risk groups
•
Small confidence intervals
•
No influence of AHT
α/β of prostate cancer
α/β (95% CI) (Gy)
All patients
1.4 (0.9 – 2.2)
Low Risk
0.6 ( 0 – 1.5)
Intermediate Risk
1.7 (0.9 – 3.6)
High Risk
1.6 (0.8 – 2.7)
19
ESTRO SBRT Course 2014 - Emerging SBRT indications
SBRT for prostate cancer